Behrendt Raymond, Huber Simon, White Peter
Merck & Cie, Im Laternenacker 5, 8200, Schaffhausen, Switzerland.
Merck Chemicals Ltd., Padge Road, Beeston, NG9 2JR, UK.
J Pept Sci. 2016 Feb;22(2):92-7. doi: 10.1002/psc.2844. Epub 2016 Jan 11.
In our efforts to develop a universal solution to the problem of aspartimide formation in Fmoc SPPS, we investigated the application of our new β-trialkylmethyl protected aspartic acid building blocks to the synthesis of peptides containing the Asp-Gly motif. The N(α)-Fmoc aspartic acid β-tri-(ethyl/propyl/butyl)methyl esters were used in the synthesis of the classic model peptide scorpion toxin II (VKDGYI), and their effectiveness in minimising aspartimide formation during extended piperidine treatments was evaluated. Furthermore, we compared their efficacy against that of the commonly used approach of adding acids to the Fmoc deprotection solution. Finally, we applied our aspartic acid building blocks to the stepwise Fmoc SPPS of teduglutide, a human GLP-2 analogue, whose synthesis is made challenging by extensive aspartimide formation. In all experiments, our approach led to almost complete reduction of aspartimide formation with accompanied suppression of aspartic acid epimerisation.
在我们努力开发一种通用解决方案以解决Fmoc固相肽合成中天冬酰胺形成问题的过程中,我们研究了新型β-三烷基甲基保护的天冬氨酸构建块在含Asp-Gly基序肽合成中的应用。N(α)-Fmoc天冬氨酸β-三(乙基/丙基/丁基)甲酯用于经典模型肽蝎毒素II(VKDGYI)的合成,并评估了它们在延长哌啶处理过程中减少天冬酰胺形成的有效性。此外,我们将它们的效果与在Fmoc脱保护溶液中添加酸的常用方法的效果进行了比较。最后,我们将天冬氨酸构建块应用于替度鲁肽(一种人GLP-2类似物)的逐步Fmoc固相肽合成中,其合成因广泛的天冬酰胺形成而具有挑战性。在所有实验中,我们的方法几乎完全减少了天冬酰胺的形成,同时抑制了天冬氨酸的差向异构化。